EUVIMEDEUVIMED entdecken
Vergleichsstudie

Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide

Shanshan Hu iD, Chenyang Shi iD, Yuhang Ma iD, Shuowen Wang, Shengying Gu, Chendong Qi, Guorong Fan iD

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15645 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Shanshan Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Cost-Benefit Analysis, Quality-Adjusted Life Years. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Research Fund for Clinical Pharmacy of China International Medical Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate the most matchable price of tirzepatide (TIRZ) compared with semaglutide (SEMA) in the treatment of type 2 diabetes in China.

Methods

The patient cohort and clinical efficacy data were derived from the SURPASS‐2 trial. Cost‐utility analysis and a binary search were performed to identify the most matchable price of TIRZ from a Chinese healthcare provider's perspective.

Results

After lifetime simulation, the quality‐adjusted life years of TIRZ 5, 10, 15 mg and SEMA 1 mg were 11.17, 11.21, 11.27 and 11.12 years, respectively. Despite an initial assumption that the annual cost of TIRZ equals that of SEMA, our analysis revealed that TIRZ is probably more cost‐effective than SEMA. A thorough evaluation of pricing showed that the cost ranges for TIRZ at doses of 5, 10 and 15 mg were $1628.61‐$1846.23, $1738.40‐$2140.95 and $1800.30‐$2430.81, respectively. After adjustment in the univariate sensitivity analysis, the cost ranges for TIRZ 5, 10 and 15 mg were $1542.68‐$1757.57, $1573.00‐$1967.16 and $1576.54‐$2133.96, respectively. These cost intervals were validated through robust probabilistic sensitivity analysis and scenario analysis, except for the cost range for TIRZ 5 mg.

Conclusions

This study shows that, using SEMA as a reference, the annual costs for TIRZ 10 and 15 mg are $1573.00‐$1967.16 and $1576.54‐$2133.96, respectively, for patients with type 2 diabetes in China.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesCost-Benefit AnalysisQuality-Adjusted Life YearsHypoglycemic AgentsDrug CostsHumansChinaMaleFemaleMiddle AgedGlucagon-Like Peptide-2 ReceptorGastric Inhibitory PolypeptideTirzepatideSemaglutide

Stichwörter der Autor:innen

GLP‐1 receptor agonistcost‐utility analysisdrug pricingsemaglutidetirzepatidetype 2 diabetes

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsGlucagon-Like Peptide-2 ReceptorGastric Inhibitory PolypeptideTirzepatideSemaglutide

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Shanshan Hu, Chenyang Shi, Yuhang Ma, Guorong Fan

Förderung

  • Research Fund for Clinical Pharmacy of China International Medical Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Hu, S., Shi, C., Ma, Y., Wang, S., Gu, S., Qi, C., & Fan, G. (2024). Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15645

Vancouver

Hu S, Shi C, Ma Y, Wang S, Gu S, Qi C, et al. Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15645

BibTeX
@article{Hu2024,
  author = {Hu, Shanshan and Shi, Chenyang and Ma, Yuhang and Wang, Shuowen and Gu, Shengying and Qi, Chendong and Fan, Guorong},
  title = {Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15645}
}
Kostenlos starten →